Over the years, TRIM28 was found to be amplified in most human cancers, and increased TRIM28 expression correlates with poor patient prognosis in multiple tumor types, including ovarian, lung, glioma, and prostate (25, 36–38). Here, TRIM28 is linked to glioma.